生物制剂时代银屑病关节炎临床试验患者人群特征的演变
该研究系统检索并选取12项II期和III期银屑病关节炎试验,按生物制剂时期与作用机制分为三个治疗阶段,比较各阶段可用患者及疾病参数。统计分析显示三个阶段的患者在人口学特征、疾病特征、疾病活动度、疾病影响及既往治疗使用方面存在显著差异,提示临床试验所考虑的患者人群随生物制剂引入而明显演变;作者指出尚需进一步研究观察这些变化能否在日常临床实践中体现。
要点
- 生物制剂引入后,银屑病关节炎临床试验入选患者的特征随时期显著变化。
- 三个阶段在人口学、疾病活动度、疾病影响及既往治疗使用上均有显著差异。
- 这些试验人群变化能否反映真实临床实践的改变尚待进一步研究。
核心结论
- 自生物制剂引入以来,银屑病关节炎临床试验所考虑的患者人群特征呈现明显演变。
- 尚需进一步研究以判断上述变化是否能在日常临床实践中被观察到。
研究设计与样本
- 系统检索并选取12项银屑病关节炎II期和III期试验。
- 按时间阶段及所涉生物制剂的作用机制将试验划分为三个治疗阶段。
- 选取三个阶段均有数据可用的患者与疾病参数,按阶段汇总并检验阶段间差异是否具有统计学显著性。
主要发现
- 统计分析显示三个治疗阶段的患者人群在患者特征、疾病特征、疾病活动度、疾病影响及既往治疗使用方面存在显著差异。
- 研究未报告各参数的具体数值、样本量或P值。
临床怎么用
- 解读银屑病关节炎临床试验结果及跨时期比较时,需考虑入选患者人群特征已随生物制剂时代发生演变。
- 该演变可作为临床实践变化的间接参考,但尚需在真实临床实践中进一步验证。
局限性
- 作者指出,这些变化能否在日常临床实践中被检测到仍需进一步研究。
- 原文摘要未报告各参数具体数值、样本量及P值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Psoriatic arthritis is a chronic inflammatory disease that affects the musculoskeletal system. It can include arthritis, spondylitis, dactylitis and enthesitis, and is strongly associated with the presence of psoriasis. The introduction of biological therapies as a treatment option has brought a significant improvement in disease control for patients with psoriatic arthritis. Here, we aimed to detect emerging differences in demographic and clinical characteristics of the psoriatic arthritis patient study population since the introduction of biologicals. We hypothesised that evolving views on control of disease activity and increased experience in the management of psoriatic arthritis have affected the patient population considered for clinical trials and that this may serve as a proxy for changes in clinical practice. METHODS: We systematically searched for and selected 12 phase II and phase III trials and divided them into three treatment periods based on different time periods and working mechanisms of the particular biologicals. We made a selection of patient and disease parameters for which data were available in all three periods, calculated those data per period and looked for statistically significant differences between the treatment periods. RESULTS: Statistical analysis showed significant differences in patient characteristics, disease characteristics, disease activity, disease effects and use of prior treatments between the patient populations of the three periods. CONCLUSION: This study shows a clear evolution of the patient population considered for clinical trials since the introduction of biologicals. Further research is needed to see if those changes can be detected in the daily clinical practice.
引用
- Vandendorpe AS, de Vlam K, Lories R, et al. Evolution of psoriatic arthritis study patient population characteristics in the era of biological treatments. RMD Open. 2019. PMID: 30740243. doi:10.1136/rmdopen-2018-000779
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。